

Iowa Medicaid Drug Utilization Review (DUR) Commission

February 2, 2022

Location: Teleconference (Due to COVID-19)

Time: 9:30 a.m. – 1:30 p.m. CT

WebEx Meeting Link:

<https://changehealthcare.webex.com/changehealthcare/j.php?MTID=mb1b8907e09458060c1fff4d0374439fb>

Dial In: 1-844-245-7693

Meeting Number: 2535 816 2346

Meeting Password: Y2cMxyDS7k2

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
2. Commission Business
 - a) Approval of the Minutes
 - b) November 2021 DUR Recommendation Letter to DHS
 - c) November 2021 P&T Recommendation Letter to DUR
 - d) Follow-Up from Previous Meeting(s)
3. IME Pharmacy Update
4. Prevalence Report Summaries
 - a) Amerigroup
 - b) Iowa Total Care
 - c) Fee-for-Service
 - d) Comparative Summary
5. Public Comment* ([Complete Speaker Conflict of Interest Disclosure Form](#))
 - Verbal - Must pre-register to provide verbal public comment and submit a completed conflict of interest disclosure.
 - Written - Must submit written comments and a completed conflict of interest disclosure.
 - Reference complete public comment policy [here](#).
 - **All submissions must be received no later than 4:30 p.m. CT January 26, 2022.**
 - Send to info@iadur.org **Indicate in email if providing written comment or verbal comment.**
6. Retrospective DUR
 - a) Data Presentation(s)
 - i. Concurrent use of GLP-1 RA and DPP-4 Inhibitors

- ii. High Dose Glucocorticoid without Bisphosphonate
- iii. SABA Overutilization
- iv. Concurrent Opioids and Benzodiazepines – Additional Information
- v. Chronic Use of Controlled Sedative/Hypnotic Agents

b) Proposal(s)

- i. Duplicate Therapy with Stimulants

c) Commission Recommendations for Retrospective DUR Agenda Topics

7. Prospective DUR

- a) Review of Current Oral Benzodiazepine Quantity Limits – Additional Information
- b) Anticonvulsant Quantity Limits – Initial Review

8. Break (10 minutes)

9. Prior Authorization

- a) PCSK9 Inhibitors – Initial Review
- b) Finerenone (Kerendia) – Initial Review
- c) Odevixibat (Bylvay) – Initial Review
- d) Pegcetacoplan (Empaveli) – Initial Review
- e) Select Preventative Migraine Treatments – Second Review
- f) Hepatitis C Treatments, Direct Acting Antivirals – Second Review
- g) Janus Kinase Inhibitors – Second Review
- h) Apremilast (Otezla) – Second Review
- i) Biologicals for Arthritis – Second Review
- j) Triheptanoin (Dojolvi) – Second Review
- k) Baclofen Oral Solution (Ozobax) – Second Review
- l) Tasimelteon (Hetlioz) – Update to Criteria

10. Miscellaneous

- a) DUR Digest Vol. 34, No. 1 – Second Review
- b) MedWatch

[FDA Approves First Drug to Improve Growth in Children with Most Common Form of Dwarfism](#)

[FDA Approves First Drug to Prevent Graft Versus Host Disease](#)

[FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease](#)

[FDA approves drug to treat sickle cell disease in patients aged 4 up to 11 years](#)

11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on. Any individual speaking, presenting, or providing written comment for virtual meetings must complete a [conflict of interest disclosure](#). Completed forms must be provided to DUR staff at least one week prior to

the scheduled meeting at info@iadur.org. Speakers who fail to submit or turn in their conflict of interest disclosure form late will have their request to speak denied or will not have their comments shared.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515)974-3131.

**Next Meeting
May 4, 2022
Location TBD**